TABLE 3.
Baseline characteristics and serial ADAMTS13 activity levels of patients with TTP.
| No. | Sex | Age | Comorbidity | Initial presentation |
PLASMIC score |
ADAMTS13 (%)* |
Relapsed/ refractory |
ADAMTS13 (%)_DOF |
ADAMTS13 (%)_DOF |
| 1 | F | 51 | Nil | Altered consciousness | 6 | 0 | Yes | 0 4 days |
0 15 days |
| 2 | F | 40 | Nil | Petechia | 7 | 0 | No | ||
| 3 | F | 22 | Nil | Syncope | 6 | 0 | No | ||
| 4 | M | 70 | T2DM HTN | Drowsiness | 6 | 0 | Yes | 0 106 days |
|
| 5 | F | 33 | SLE | Dizziness | 7 | 0 | Yes | 0 57 days |
24 384 days |
| 6 | M | 61 | HBV | Dizziness | 6 | 0 | No | ||
| 7 | F | 34 | SLE | Headache | 7 | 0 | No | ||
| 8 | F | 62 | HTN | Headache | 6 | 0 | No | ||
| 9 | F | 37 | SLE | Petechia | 6 | 0 | No |
ADAMTS13, a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13; TTP, thrombotic thrombocytopenic purpura; T2DM, type 2 diabetes mellitus; HTN, hypertension; SLE, systemic lupus erythematosus; HBV, chronic hepatitis B infection; ADAMTS13(%)*: ADAMTS13 activity level at presentation; DOF: days of follow-up after first ADAMTS13 activity result.